Tyrosinase-activated prodrug nanomedicine as oxidative stress amplifier for melanoma-specific treatment.
Acetaminophen
Melanoma treatment
Nano-prodrug
Oxidative stress
Tyrosinase activation
Journal
Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
18
03
2020
revised:
10
08
2020
accepted:
13
08
2020
pubmed:
25
8
2020
medline:
15
5
2021
entrez:
25
8
2020
Statut:
ppublish
Résumé
Malignant melanoma is one of the most aggressive skin cancers, posing severe threat to human health. Tyrosinase, overexpressed in melanoma cells, is a specific in-situ weapon to augment the therapeutic efficacy of melanoma-specific treatment by in-situ accelerating the activation of anti-melanoma prodrugs. Herein, we developed a tyrosinase-triggered oxidative stress amplifier, denoted as APAP@PEG/HMnO
Identifiants
pubmed: 32836058
pii: S0142-9612(20)30575-5
doi: 10.1016/j.biomaterials.2020.120329
pii:
doi:
Substances chimiques
Prodrugs
0
Reactive Oxygen Species
0
Hydrogen Peroxide
BBX060AN9V
Monophenol Monooxygenase
EC 1.14.18.1
Glutathione
GAN16C9B8O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
120329Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.